title: Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.
authors.affiliation: The University of Chicago Pritzker School of Medicine, 150 East Huron, Chicago, IL 60611, USA.
authors.forename: Michael H
authors.initials: MH
authors.lastname: Davidson
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D001384:Azetidines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D001384:Azetidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D043484:Proprotein Convertases
references.citation: Nat Rev Cardiol. 2011 May;8(5):253-65
references.pmid: 21321561
references.citation: Eur Heart J. 2010 Dec;31(23):2844-53
references.pmid: 20965889
references.citation: N Engl J Med. 2006 Mar 23;354(12):1264-72
references.pmid: 16554528
references.citation: J Lipid Res. 2007 Jul;48(7):1488-98
references.pmid: 17449864
references.citation: Lancet. 2012 Dec 8;380(9858):2007-17
references.pmid: 23141813
references.citation: Circulation. 2013 Aug 27;128(9):962-9
references.pmid: 23884353
references.citation: Atherosclerosis. 2009 Mar;203(1):166-71
references.pmid: 19081568
references.citation: Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9546-7
references.pmid: 19506257
references.citation: Nat Genet. 2005 Feb;37(2):161-5
references.pmid: 15654334
references.citation: N Engl J Med. 2009 Dec 24;361(26):2573-4
references.pmid: 20032327
references.citation: J Lipid Res. 2012 Dec;53(12):2515-24
references.pmid: 22811413